Home Drug IndexClinical Monograph

Ceftriaxone Uses, Dosage, Side Effects & Price | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antibacterial

Subclass

Third-Generation Cephalosporin

Speciality

Infectious Disease

Schedule (India)

Schedule H

Routes

Intravenous (IV), Intramuscular (IM)

Formulations

Form	Strengths
Powder for Injection (IV/IM)	250 mg; 500 mg; 1 g; 2 g per vial
Fixed-Dose Combinations	Ceftriaxone + Sulbactam (1 g + 500 mg; 1.5 g combination); Ceftriaxone + Tazobactam (1 g + 125 mg)

Reconstitution Notes:

IV: Reconstitute with Sterile Water for Injection or compatible IV fluid
IM: Reconstitute with 1% Lidocaine (without adrenaline) to reduce injection pain — Lidocaine-containing solution must NOT be used for IV administration

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Community-Acquired Pneumonia (CAP)

Adults:

Parameter	Recommendation
Starting dose	1 g IV/IM once daily
Titration	Increase to 2 g once daily for severe pneumonia
Usual maintenance dose	1–2 g once daily
Maximum dose	4 g/day (given as 2 g every 12 hours if >2 g/day required)
Duration	5–7 days; extend to 10–14 days for severe or complicated cases

Clinical Note: For severe CAP requiring ICU admission, consider combination with macrolide (azithromycin) or fluoroquinolone for atypical coverage.

2. Bacterial Meningitis

Adults:

Parameter	Recommendation
Starting dose	2 g IV every 12 hours
Titration	Not applicable
Usual maintenance dose	2 g IV every 12 hours (4 g/day total)
Maximum dose	4 g/day
Duration	7 days (meningococcal); 10–14 days (pneumococcal); 21 days (Listeria — add ampicillin)

Clinical Note: Higher doses and shorter dosing intervals essential for adequate CSF penetration. Add dexamethasone before or with first antibiotic dose for suspected bacterial meningitis.

3. Enteric Fever (Typhoid/Paratyphoid)

Adults:

Parameter	Recommendation
Starting dose	2 g IV/IM once daily
Titration	Not applicable
Usual maintenance dose	2 g once daily
Maximum dose	2 g/day (some protocols allow up to 4 g/day in severe cases)
Duration	10–14 days; minimum until afebrile for 5 days

Clinical Note: Preferred parenteral agent for multi-drug resistant (MDR) and fluoroquinolone-resistant typhoid, which is increasingly common in India. Blood culture before initiation recommended where feasible.

4. Uncomplicated Gonorrhoea (Urethritis/Cervicitis)

Adults:

Parameter	Recommendation
Starting dose	250 mg IM as single dose (Indian practice) OR 500 mg IM single dose (per updated guidelines)
Titration	Not applicable
Usual maintenance dose	Not applicable (single-dose therapy)
Maximum dose	500 mg single dose
Duration	Single dose

Clinical Note: Always co-treat with azithromycin 1 g orally single dose (dual therapy) to cover potential chlamydial co-infection and reduce gonococcal resistance emergence. Higher dose (500 mg) increasingly recommended due to rising MICs.

5. Intra-Abdominal Infections (Including Peritonitis, Cholangitis)

Adults:

Parameter	Recommendation
Starting dose	1–2 g IV once daily
Titration	Not applicable
Usual maintenance dose	2 g once daily
Maximum dose	4 g/day (in severe infections)
Duration	5–14 days depending on source control and clinical response

Clinical Note: Add metronidazole for anaerobic coverage in mixed intra-abdominal infections.

6. Skin and Soft Tissue Infections (Complicated)

Adults:

Parameter	Recommendation
Starting dose	1 g IV/IM once daily
Titration	Increase to 2 g once daily for severe infections
Usual maintenance dose	1–2 g once daily
Maximum dose	4 g/day
Duration	7–14 days

7. Bone and Joint Infections (Osteomyelitis, Septic Arthritis)

Adults:

Parameter	Recommendation
Starting dose	2 g IV once daily
Titration	Not applicable
Usual maintenance dose	2 g once daily
Maximum dose	4 g/day (divided doses if >2 g)
Duration	4–6 weeks (osteomyelitis); 3–4 weeks (septic arthritis)

Clinical Note: Requires culture-guided therapy. Often used as empirical agent pending sensitivity results. Orthopaedic/infectious disease specialist input recommended for prolonged courses.

8. Urinary Tract Infections (Complicated/Pyelonephritis)

Adults:

Parameter	Recommendation
Starting dose	1 g IV/IM once daily
Titration	Increase to 2 g once daily for severe pyelonephritis or urosepsis
Usual maintenance dose	1–2 g once daily
Maximum dose	4 g/day
Duration	10–14 days; step-down to oral therapy when clinically stable

9. Surgical Prophylaxis

Adults:

Parameter	Recommendation
Starting dose	1 g IV, 30–60 minutes before surgical incision
Titration	Not applicable
Usual maintenance dose	Not applicable (single pre-operative dose)
Maximum dose	2 g for high-risk or colorectal surgery
Duration	Single dose; redose if surgery prolonged (>4 hours) or significant blood loss

Clinical Note: Appropriate for clean-contaminated procedures. Not routinely recommended for clean procedures unless prosthetic material involved.

10. Sepsis / Septicaemia (Empirical Therapy)

Adults:

Parameter	Recommendation
Starting dose	2 g IV once daily (or 1 g every 12 hours)
Titration	Not applicable
Usual maintenance dose	2 g once daily
Maximum dose	4 g/day
Duration	As per culture-sensitivity and source; typically 7–14 days

Clinical Note: Empirical choice for community-acquired sepsis. Not effective against MRSA, Pseudomonas, or ESBL-producers — escalate if these are suspected.

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Notes
Spontaneous Bacterial Peritonitis (SBP)	2 g IV once daily	5 days	OFF-LABEL. Standard practice in Indian hepatology centres (AIIMS, PGI protocols). Culture ascitic fluid before starting. Step-down to oral fluoroquinolone if sensitive
Lyme Disease (Early disseminated/Late — Neuroborreliosis)	2 g IV once daily	14–28 days	OFF-LABEL. Rare in India; relevant for travellers returning from endemic areas
Infective Endocarditis (Native valve — Streptococcal)	2 g IV once daily	4 weeks (with or without gentamicin)	OFF-LABEL. Specialist use only. Based on AHA/ESC guidelines adapted in tertiary centres

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

1. Bacterial Meningitis

Neonates (≤28 days):

Parameter	Recommendation
Starting dose	50 mg/kg IV once daily
Titration	Not applicable
Usual maintenance dose	50 mg/kg once daily
Maximum dose	50 mg/kg/day (do not exceed 2 g/day)
Duration	14–21 days depending on organism

Infants and Children (>28 days to 12 years):

Parameter	Recommendation
Starting dose	50 mg/kg IV
Titration	Not applicable
Usual maintenance dose	80–100 mg/kg/day divided every 12 hours
Maximum dose	4 g/day
Duration	7–14 days depending on pathogen

2. Community-Acquired Pneumonia (Severe/Hospitalised)

Infants and Children:

Parameter	Recommendation
Starting dose	50 mg/kg IV/IM once daily
Titration	Not applicable
Usual maintenance dose	50–75 mg/kg once daily
Maximum dose	2 g/day
Duration	5–10 days

3. Enteric Fever (Typhoid)

Infants and Children:

Parameter	Recommendation
Starting dose	50 mg/kg IV/IM once daily
Titration	Not applicable
Usual maintenance dose	75 mg/kg once daily
Maximum dose	2 g/day
Duration	10–14 days; minimum until afebrile for 5 days

Clinical Note: Preferred parenteral agent for MDR typhoid in children.

4. Sepsis / Severe Bacterial Infections

Neonates:

Age	Dose	Frequency	Maximum
0–7 days	50 mg/kg	Once daily	50 mg/kg/day
8–28 days	50–75 mg/kg	Once daily	75 mg/kg/day

Infants and Children:

Parameter	Recommendation
Starting dose	50 mg/kg IV
Usual maintenance dose	50–80 mg/kg/day in 1–2 divided doses
Maximum dose	4 g/day

5. Uncomplicated Gonorrhoea (Adolescents ≥45 kg)

Parameter	Recommendation
Dose	250–500 mg IM single dose
Duration	Single dose

Clinical Note: Co-treat with azithromycin. NACO STI guidelines applicable.

6. Surgical Prophylaxis (Paediatric)

Parameter	Recommendation
Dose	50 mg/kg IV (max 1 g) 30–60 minutes before incision
Duration	Single dose

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Dose	Duration	Notes
SBP in Paediatric Liver Disease	50–75 mg/kg IV once daily (max 2 g)	5–7 days	OFF-LABEL. Specialist hepatologist only. Monitor for biliary sludging

Age Restrictions and Special Neonatal Precautions

Population	Recommendation
Preterm neonates (<41 weeks postmenstrual age)	Use with extreme caution; risk of bilirubin displacement and kernicterus
Hyperbilirubinaemic neonates	AVOID ceftriaxone; use alternative cephalosporin (cefotaxime preferred)
Neonates receiving calcium-containing IV fluids	CONTRAINDICATED due to fatal ceftriaxone-calcium precipitation
Term neonates (>41 weeks) without hyperbilirubinaemia	May use with caution; avoid concurrent calcium infusions

Safety Monitoring in Paediatrics:

Bilirubin levels in neonates at risk
Ultrasound if prolonged therapy (>14 days) — assess for biliary sludging/pseudolithiasis
Renal and hepatic function in prolonged courses
Signs of superinfection (oral thrush, diarrhoea)

Renal Adjustments

eGFR (mL/min)	Recommendation
>10	No dose adjustment required
≤10 (without hepatic impairment)	No dose adjustment required; monitor closely
≤10 (with concurrent hepatic impairment)	Maximum 2 g/day
Haemodialysis	Not significantly removed; no supplemental dose required post-dialysis
Peritoneal dialysis	No supplemental dose required
CRRT	Standard dosing; monitor clinical response

Clinical Note: Ceftriaxone has dual elimination (hepatic and renal). Dose reduction only needed when both routes are severely impaired.

Hepatic adjustment

Contraindications

Known hypersensitivity to ceftriaxone or any cephalosporin antibiotic
History of severe (anaphylactic) hypersensitivity reaction to any beta-lactam antibiotic
Hyperbilirubinaemic neonates, especially preterm infants (<41 weeks postmenstrual age)
Neonates requiring (or expected to require) calcium-containing IV infusions including parenteral nutrition
Full-term neonates (<28 days) if concomitant IV calcium administration is anticipated
Reconstitution with calcium-containing diluents (e.g., Ringer's lactate, Hartmann's solution)

Cautions

History of non-severe penicillin allergy — cross-reactivity risk approximately 1–2% (higher with aminopenicillins); observe for allergic reactions
Prolonged therapy (>14 days) — risk of biliary sludging/gallbladder pseudolithiasis (especially in children, fasting patients, those on TPN)
Dehydration or restricted fluid intake — increased risk of biliary precipitation
History of gastrointestinal disease, particularly colitis — risk of Clostridioides difficile-associated diarrhoea
Concurrent aminoglycoside use — additive nephrotoxicity; administer separately and monitor renal function
Premature neonates — use cefotaxime preferentially to avoid bilirubin displacement risk
IM administration — painful injection; use lidocaine 1% for reconstitution (never for IV use)

Pregnancy

Parameter	Recommendation
Overall safety	Generally considered safe; widely used in pregnancy
Risk category	Category B (US legacy); no formal India classification; extensive clinical experience supports safety
Preferred alternatives	Ceftriaxone is often preferred parenteral cephalosporin in pregnancy for serious infections
When to use	For serious infections (typhoid, pneumonia, pyelonephritis, sepsis) when parenteral therapy required
Monitoring	Hypersensitivity reactions; CBC and LFTs if prolonged use; standard foetal monitoring

Lactation

Parameter	Recommendation
Compatibility	Compatible with breastfeeding
Drug levels in milk	Low (approximately 3–4% of maternal dose); clinically insignificant
Preferred alternatives	None required; ceftriaxone acceptable during breastfeeding
Infant monitoring	Observe for loose stools, oral thrush, or rash (rare)

Elderly

Parameter	Recommendation
Starting dose	Standard adult dosing; no age-related reduction required
Titration	Not applicable
Specific considerations	Assess renal function (serum creatinine may underestimate impairment); ensure adequate hydration to reduce biliary precipitation risk
Additional risks	Higher risk of Clostridioides difficile infection; increased susceptibility to biliary complications if malnourished or prolonged fasting
Monitoring	Renal function; hepatic function in prolonged therapy; signs of superinfection

Major drug interactions

Drug	Interaction	Recommendation
Calcium-containing IV solutions (Ringer's lactate, Hartmann's, calcium gluconate, TPN with calcium)	Risk of ceftriaxone-calcium precipitate formation — can be fatal in neonates; lung/kidney precipitation reported	CONTRAINDICATED in neonates. In adults/children, administer through separate lines; flush between infusions; do not mix in same bag/syringe
Warfarin/Acenocoumarol	Enhanced anticoagulant effect; mechanism includes vitamin K antagonism via gut flora disruption and possible direct effect	Monitor INR closely during and for several days after ceftriaxone course; adjust anticoagulant dose as needed
Aminoglycosides (Amikacin, Gentamicin)	Additive nephrotoxicity; also physical incompatibility if mixed	Administer separately via different lines/sites; monitor serum creatinine and aminoglycoside levels

Moderate drug interactions

Drug	Interaction	Recommendation
Loop diuretics (Furosemide)	Theoretical increased nephrotoxicity risk	Generally safe; monitor renal function, especially in dehydrated patients
Probenecid	Decreases renal tubular secretion of ceftriaxone; increases plasma levels	Usually not clinically significant due to hepatic elimination; no dose adjustment typically needed
Oral contraceptives	Theoretical reduction in efficacy via gut flora alteration	Advise additional barrier contraception during antibiotic course and for 7 days after (precautionary)
Chloramphenicol	Potential antagonism (bacteriostatic vs bactericidal)	Avoid combination where possible; if used, monitor clinical response closely

Common Adverse effects

Injection site pain and induration (IM route)
Phlebitis/thrombophlebitis (IV route)
Diarrhoea
Nausea and vomiting
Skin rash (maculopapular)
Transient elevation of liver enzymes (AST, ALT)
Eosinophilia
Biliary sludging/pseudolithiasis (especially with prolonged use, higher doses, or fasting)
Positive direct Coombs test (usually without haemolysis)

Serious Adverse effects

Adverse Effect	Clinical Notes
Anaphylaxis	Rare but potentially fatal; discontinue immediately; manage with adrenaline and supportive care
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis	Very rare; discontinue immediately; requires hospitalisation
Immune haemolytic anaemia	Rare; can be severe; discontinue ceftriaxone permanently
Clostridioides difficile-associated diarrhoea (CDAD)	May occur during or after therapy; discontinue ceftriaxone if confirmed; treat with oral vancomycin or metronidazole
Biliary obstruction (from pseudolithiasis)	Usually reversible upon drug discontinuation; ultrasound for diagnosis
Ceftriaxone-calcium precipitation (neonates)	Fatal cardiopulmonary reactions reported; strictly avoid concurrent calcium infusions in neonates
Seizures	Rare; reported with very high doses or in renal impairment
Interstitial nephritis	Rare; presents with fever, rash, eosinophilia, rising creatinine
Agranulocytosis / Neutropenia	Rare; monitor CBC in prolonged therapy

Monitoring requirements

Phase	Parameters
Baseline	Serum creatinine, LFTs, CBC, allergy history (especially to penicillins/cephalosporins); bilirubin in neonates
During treatment	Clinical response; signs of hypersensitivity; GI tolerance; injection site (for phlebitis/pain)
Prolonged therapy (>7 days)	LFTs weekly; CBC; renal function; ultrasound abdomen if >14 days (especially in children) to assess for biliary sludging
If on anticoagulants	INR monitoring during and after ceftriaxone course
Neonates	Bilirubin levels; avoid concurrent calcium; monitor for precipitation-related complications

Brands in India

Brand Name	Manufacturer
Monocef	Aristo
Ceftriaxone (Generic)	Multiple manufacturers
Taxim	Alkem
Oframax	Unidentified
Xone	Alkem
Cefaxone	Lupin
LupiCef	Lupin
Ceftriax	Cadila
Monotax	Zydus

Fixed-Dose Combinations:

Monocef-SB, Magnex (Ceftriaxone + Sulbactam)
Intacef Tazo (Ceftriaxone + Tazobactam)

Price range (INR)

Formulation	Approximate Price
250 mg vial	₹15–₹40
500 mg vial	₹25–₹60
1 g vial	₹30–₹80
2 g vial	₹70–₹150
Ceftriaxone + Sulbactam 1.5 g	₹80–₹180

Regulatory Note: Listed under NLEM 2022. Prices regulated by NPPA for scheduled strengths. Available through government supply (NRHM, hospital pharmacies) at significantly lower rates.

Clinical pearls

Once-daily dosing advantage: Long half-life (6–8 hours) allows once-daily administration for most indications except meningitis, simplifying inpatient and outpatient parenteral therapy.
Calcium contraindication in neonates is absolute: Fatal cardiopulmonary precipitation reported. If ceftriaxone essential, ensure 48-hour gap from any calcium-containing infusion. Cefotaxime is safer alternative in neonates.
IM injection technique: Reconstitute with 1% lidocaine (without adrenaline) for IM use to reduce pain. Never use lidocaine-containing solution for IV administration.
Biliary sludging is reversible: If gallbladder pseudolithiasis occurs (more common with >14 days therapy or fasting patients), it typically resolves spontaneously after stopping ceftriaxone.
Empirical typhoid therapy: Ceftriaxone is preferred parenteral agent in India given high fluoroquinolone resistance. Continue for 10–14 days for optimal cure rates.
Not effective against: MRSA, Pseudomonas aeruginosa, Enterococcus species, ESBL-producing Enterobacteriaceae, Acinetobacter. Escalate therapy if these organisms suspected.

Version

RxIndia v1.0 — 20 Apr 2025

Reference

- CDSCO Drug Database and Product Inserts
- Indian Pharmacopoeia 2022
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine (11th Edition)
- AIIMS Antibiotic Guidelines and Treatment Protocols
- IAP Antimicrobial Guidelines for Paediatric Practice
- ICMR Guidelines for Antimicrobial Use
- NACO STI/RTI Treatment Guidelines
- ILBS/PGI Hepatology Protocols (for SBP)
- WHO Essential Medicines List (supportive reference)
- Goodman & Gilman's The Pharmacological Basis of Therapeutics

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...